← FDA DRUG APPROVALS

FDA ANDA · ANDA216809

KETAMINE HYDROCHLORIDE

Sponsor: GLAND

APPLICATION
ANDA216809
TYPE
ANDA
ORIGINAL APPROVAL
2023-01-24
LATEST ACTION
2026-03-27
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

KETAMINE HYDROCHLORIDEPrescription
KETAMINE HYDROCHLORIDE EQ 10MG BASE/ML · INJECTABLE · INJECTION
KETAMINE HYDROCHLORIDEPrescription
KETAMINE HYDROCHLORIDE EQ 50MG BASE/ML · INJECTABLE · INJECTION
KETAMINE HYDROCHLORIDEPrescription
KETAMINE HYDROCHLORIDE EQ 100MG BASE/ML · INJECTABLE · INJECTION

Approval history

2026-03-27Labeling · Supplement 3 · standardAP
2023-01-24UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →